< Previous Article
September 2022Volume 2, Issue 1, Pages 253–266
Switch to Standard ViewSwitch to Enhanced View

Recent Advances in Psychopharmacology

Alexander J. Poznanski
x
Alexander J. Poznanski
Search for articles by this author

Correspondence

  • Corresponding author.
, MD∗,'Correspondence information about the author MD Alexander J. Poznanski
x
Alexander J. Poznanski
Search for articles by this author

Correspondence

  • Corresponding author.
,
Esther Akinyemi
x
Esther Akinyemi
, MD
Department of Behavioral Health, Henry Ford Health, One Ford Place, 1COO, Detroit, MI 48202, USA
Recent Advances in Psychopharmacology
DOI: https://doi.org/10.1016/j.ypsc.2022.03.009
|

To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect.

First page of article

There is a better understanding of mental illness and the potential underlying mechanisms leading to new medications with novel mechanisms of action. The new medications seek to reduce side effects while optimizing efficacy. Attention-deficit hyperactivity disorder, mood disorders, movement disorders, neurocognitive disorders, psychotic disorders, sexual disorders, and sleep disorders have all had newly approved medications in the last 5 years. Some of the new indications are of older medications being explored for other indications. This article describes these medications, the trials supporting them, and relevant clinical information about each medication.

Keywords:

Aducanumab, Hypnotics, ADHD, Bremelanotide, Brexanolone, Esketamine, New antipsychotics

To access this article, please choose from the options below

Log In


Register

Create a new account

Purchase access to this article

Claim Access

If you are a current subscriber with Society Membership or an Account Number, claim your access now.

Subscribe to this title

Purchase a subscription to gain access to this and all other articles in this journal.

Institutional Access

Visit ScienceDirect to see if you have access via your institution.

© 2022 Elsevier Inc. All rights reserved.
Access this article on
ScienceDirect
Visit ScienceDirect to see if you have access via your institution.

Article Tools

 

Article Related Video

Article Related Audio

Linked Articles

Unknown widget #d2170c4d-a9cf-482f-ac17-ef77d57a1866

of type linkedContentList

Related Articles

Unknown widget #c2ffda61-8426-42f7-926b-03d7330eede2

of type relatedArticleListWidget

< Previous Article
September 2022Volume 2, Issue 1, Pages 253–266